Bing

SEARCH HISTORY

DALLAS, Dec. 8, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes financial and investment analysis, analyst consensus, and pertinent industry …
GlobeNewswire · 12/8/2009
We see limited upside potential until Allos is successful in expanding its product portfolio. The stock carries a Zacks #3 Rank (Hold rating) in the short-run.
ZACKS · 2/6/2012
Sales of the drug could reach $300 million in the US, but even if the final tally’s only $150 million, that still adds up to about $5 a share for the stock. And ALTH closed Thursday at $5.89. The stock took a hit as a result of Allos’ Oct. 7 secondary ...
CNBC · 11/5/2009
ALTH ) ? A slightly larger biotech that's still unprofitable. And a bunch of cranky investors. Allos' shareholders will receive 0.128 shares of AMAG in the all-stock merger, which valued Allos about 18% higher than the closing price on Tuesday. But AMAG's ...
The Motley Fool · ByBrian Orelli · 7/21/2011
A number of companies trading on the NASDAQ sank to 52-week lows on Tuesday including: Orexigen Therapeutic (OREX), Mannkind Corporation (MNKD), Allos Therapeutics (ALTH), Dyax Corp. (DYAX), and Life Partners Holding (LPHI). Orexigen …
OTC Equity · 2/1/2011
N/A ( c ) N a m e o f o ffe ro r/o ffe re e in re la tio n to w h o s e re le v a n t s e c u ritie s th is fo rm re la te s : Use a se p arate form for e ach offe ror/offe re e S yne rg y He alth Plc ( d ... De tails of any op e n stock-se ttle d ...
4 Traders · 7/27/2015
put open interest at 2,704 contracts (Put/Call ratio at 0.25). Short float at 11.41%, which implies a short ratio of 7.14 days. The stock has lost -10.89% over the last year. 10. Allos Therapeutics, Inc. (ALTH): Drug Manufacturers - Other Industry.
NASDAQ · 2/14/2011
Incyte's marketing partner for Jakafi ... ALTH), and Cadence Pharmaceuticals (CADX) have also experienced disappointing drug launches. Even the successful launch of a new hepatitis C drug by Vertex (NASDAQ:VRTX) has failed to buoy that company's …
Seeking Alpha · 1/24/2012
The stock is trading 13% above its 50-day moving average and 12.1% above its 200-day moving average. Trading with a volume of 4.4 million, or 5.5 times its average daily volume, Allos Therapeutics (ALTH) is up on high volume today. At $1.83, the stock ...
Fox Business · 8/29/2012
With the lower price target, Citigroup did maintain its buy rating. Shares of Allos were sharply lower on Wednesday, falling 12.1% today. Market News Video produces and distributes online videos about stocks and investing.
Forbes · 5/11/2011